Implementation Study of Treatment Optimization Recommendations on Relapsing-Remitting Multiple Sclerosis (RR MS) Subjects
Status:
Withdrawn
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Brief Summary: 800 RRMS Subjects currently treated with Avonex or Copaxone will be randomized
to either continue on their current therapy or receive Rebif therapy. The subjects will be
followed for 2 years. The primary objective is to compare the time to worsening to a medium
level of concern as defined by the Canadian Multiple Sclerosis Working Group (CMSWG)
treatment optimization recommendations.